Cracking The Code: Understanding Analyst Reviews For Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of ratings for Edwards Lifesciences (NYSE:EW) over the past three months, with a mix of bullish, somewhat bullish, and indifferent sentiments. The average 12-month price target has decreased by 11.23% to $74.33. Several analysts have lowered their price targets and ratings, reflecting a cautious outlook. Despite this, Edwards Lifesciences shows strong financial health with impressive net margins, ROE, and ROA, and a low debt-to-equity ratio.
October 25, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Edwards Lifesciences has received mixed analyst ratings, with a decrease in the average price target to $74.33. Analysts have generally lowered their ratings, indicating a cautious outlook. However, the company maintains strong financial health with high net margins, ROE, and ROA, and a low debt-to-equity ratio.
The mixed analyst ratings and lowered price targets suggest a neutral short-term impact on Edwards Lifesciences' stock price. While analysts are cautious, the company's strong financial metrics provide a counterbalance, leading to a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100